ConductScience.org, home

Comparison · NCT03176693-b1d613eb

Phenoxybenzamine vs Doxazosin: Participants Admitted to Post-operative Intensive Care Unit (ICU)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Phenoxybenzamine vs Doxazosin: Participants Admitted to Post-operative Intensive Care Unit (ICU). Trial comparisons, record NCT03176693-b1d613eb. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03176693-b1d613eb

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1050.02940.314wilson
Risk in group 20.050.008880.236wilson
Risk difference, group 1 minus group 20.0553-0.1460.268newcombe hybrid score
Risk ratio, group 1 over group 22.110.20821.4log
Odds ratio, group 1 over group 22.240.18626.9log
Number needed to treat, for one more participant with the outcome on Phenoxybenzamine than on Doxazosin18.1from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Phenoxybenzamine
3-4 weeks prior to date of surgery, patient will start phenoxybenzamine 10mg PO twice daily. Phenoxybenzamine will then be titrated to a blood pressure \<120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).~Phenoxybenzamine: Non-selective alpha blocker
219OG000
Group 2Doxazosin
3-4 weeks prior to date of surgery, patient will start doxazosin 1 mg PO daily. Phenoxybenzamine will then be titrated to a blood pressure \<120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).~Doxazosin: Selective alpha blocker
120OG001

Outcome

Type
SECONDARY
Title
Participants Admitted to Post-operative Intensive Care Unit (ICU)
Description
Time frame
up to 30 days post-surgery
Population

Source ClinicalTrials.gov

Trial

Title
Preoperative Alpha Blockade for Pheochromocytoma
NCT number
NCT03176693
Phases
PHASE3
Conditions
Pheochromocytoma, Paraganglioma
Interventions
Phenoxybenzamine, Doxazosin
Lead sponsor
University of California, Los Angeles
Results first posted
2023-11-20

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03176693-b1d613eb